# Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients

> **NCT00128310** · PHASE3 · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 252 (actual)

## Conditions studied

- Breast Cancer
- Neoplasm Metastasis

## Interventions

- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00128310
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01-18
- **Primary completion:** 2006-08-15
- **Final completion:** 2008-01-24
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2023-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128310, "Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00128310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*